MicrosoftTeams image 49 scaled
VasoDynamics attracts £1.9m from new investors

Additional funding to support the clinical development of NG11-2

30th November 2021 – VasoDynamics Ltd, the pharmaceutical company developing patient-friendly therapies for the prevention of debilitating side-effects induced by anti-cancer treatments, today announces that its has successfully raised £1.9m from two leading healthcare investors in the US and Europe, for the progression of NG11-2 into a multi-centre Phase Ib clinical trial in head-and-neck cancer patients in the UK.

Ningfeng Fiona Li, CEO of VasoDynamics, said:

“We are excited to have attracted two such high-calibre investors to help accelerate the clinical development of NG11-2 for the prevention of severe radiation-induced oral mucositis (RIOM) in head-and-neck cancer patients.”

For enquiries, please contact:

Ningfeng Fiona Li, CEO +44 7969132263
fiona.li@vasodynamics.co.uk
Gary Bower, COO +44 7960388412
gary.bower@vasodynamics.co.uk

Notes to Editors:

About VasoDynamics

VasoDynamics is a UK-based pharmaceutical development company focused on improving the standard of cancer care globally. Recognising the mounting cost pressures facing healthcare payers all over the world, VasoDynamics is developing cost-effective medicines for the prevention and treatment of debilitating and often dose-limiting complications of cancer therapy, such as chemotherapy and radiotherapy-induced mucositis, dermatitis and hair-loss. The company’s proprietary technology platform utilises the different dynamics of normal and cancerous vasculature to achieve the most effective protection of normal tissue during cancer treatment whilst enhancing anti-cancer therapy efficacy.